Medical Pharmaceutical Supply – Bupivacaine Hydrochloride Injection

The contract entails the supply and delivery of five 50-mL bottles of Bupivacaine Hydrochloride Injection, USP (0.25%) to the Department of Defense medical supply chain, requiring strict adherence to pharmaceutical standards and hazardous materials handling protocols. The product must be properly packaged and labeled in compliance with federal regulations, including cybersecurity requirements for data integrity and supply chain security. All logistics, from manufacturing to final delivery, must meet the stringent guidelines of the DoD to ensure patient safety and operational readiness. Performance is localized to Fort Bragg, North Carolina, with a submission deadline of August 3, 2026, and the contract is classified as a subcontract under NAICS code 325412 for pharmaceutical preparation manufacturing. The agency responsible is the Medical Supply Chain PHARM FSA, which oversees the integration of this pharmaceutical into the DoD’s medical inventory system. Compliance with all regulatory, safety, and documentation standards is mandatory, and the contractor must ensure uninterrupted availability and traceability of the product through the entire distribution lifecycle.